Download PDF
Thromb Haemost 2023; 123(11): 1072-1088
DOI: 10.1055/s-0043-1770100
Stroke, Systemic or Venous Thromboembolism

Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis

Zhe Li   *
1   Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China
2   Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
,
Wentao Xu   *
1   Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China
2   Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
,
Le Wang   *
1   Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China
3   Postgraduate College, China Medical University, Shenyang, China
,
Lu Chai   *
1   Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China
2   Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
,
Walter Ageno
4   Department of Medicine and Surgery, University of Insubria, Varese, Italy
,
Fernando Gomes Romeiro
5   Department of Internal Medicine, Botucatu Medical School, São Paulo State University (UNESP), São Paulo, Brazil
,
Hongyu Li
1   Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China
2   Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
3   Postgraduate College, China Medical University, Shenyang, China
,
Xingshun Qi
1   Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China
2   Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
3   Postgraduate College, China Medical University, Shenyang, China
› Author Affiliations
› Further Information
    Permissions and Reprints


Abstract

Background Direct oral anticoagulants (DOACs) are effective for the management of thromboembolic disorders. However, bleeding remains a major concern in cirrhotic patients receiving DOACs.

Methods PubMed, EMBASE, and Cochrane Library databases were searched. The incidence of bleeding episodes in cirrhotic patients receiving DOACs was pooled. Odds ratios (ORs) were calculated to compare the incidence of bleeding episodes in cirrhotic patients who received DOACs versus those who received conventional anticoagulants and did not receive anticoagulants.

Results Twenty-nine studies were included. All bleeding, major bleeding, fatal bleeding, gastrointestinal bleeding, and intracranial hemorrhage episodes were observed in 310/2,469, 100/1,388, 2/611, 166/1,886, and 5/1,147 cirrhotic patients receiving DOACs, respectively. Their pooled incidences were 13, 6, 0, 8, and 0%, respectively. They became higher in subgroup analyses of studies with advanced age, a longer treatment duration, and Child–Turcotte–Pugh class C. Compared with conventional anticoagulants, DOACs were associated with lower incidences of all bleeding (OR = 0.71, 95% confidence interval [CI] = 0.52–0.98) and major bleeding (OR = 0.55, 95% CI = 0.37–0.83) in cirrhotic patients, but not those of fatal bleeding (OR = 0.21, 95% CI = 0.04–1.28), gastrointestinal bleeding (OR = 0.78, 95% CI = 0.52–1.17), or intracranial hemorrhage (OR = 0.36, 95% CI = 0.12–1.12). The incidences of all bleeding (OR = 1.04, 95% CI = 0.22–4.79) and major bleeding (OR = 0.96, 95% CI = 0.26–3.61) did not significantly differ between cirrhotic patients with portal vein thrombosis (PVT) who received DOACs and those who did not receive anticoagulants.

Conclusion DOACs carry a low risk of bleeding in liver cirrhosis. Age, treatment duration, and Child–Turcotte–Pugh class may be associated with bleeding in cirrhotic patients receiving DOACs. The risk of bleeding is not increased by DOACs in cirrhotic patients with PVT.

Keywords

liver cirrhosis - DOACs - thrombosis - bleeding

Authors' Contribution

Conception and design: Z. L. and X. Q.; Collection and assembly of data: Z. L., W. X., and L. C.; Data analysis and interpretation: Z. L., W. X., L. W., L. C., and X. Q.; manuscript writing: Z. L., W. X., L. W., L. C., and X. Q.; Final approval of manuscript: Z. L., W. X., L. W., L. C., W. A., F. G. R., H. L., and X. Q.; Supervision: X. Q. All authors have made an intellectual contribution to the manuscript and approved the submission.


* Co-first authors.


Supplementary Material



Publication History

Received: 16 March 2023

Accepted: 12 May 2023

Article published online:
19 June 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Pan J, Wang L, Gao F. et al. Epidemiology of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Eur J Intern Med 2022; 104: 21-32
    CrossrefPubMedGoogle Scholar
  • 2 Qi X, Ren W, Guo X, Fan D. Epidemiology of venous thromboembolism in patients with liver diseases: a systematic review and meta-analysis. Intern Emerg Med 2015; 10 (02) 205-217
    CrossrefPubMedGoogle Scholar
  • 3 Ambrosino P, Tarantino L, Di Minno G. et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost 2017; 117 (01) 139-148
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 An J, Shim JH, Kim SO. et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study. Circulation 2014; 130 (16) 1353-1362
    CrossrefPubMedGoogle Scholar
  • 5 Zheng K, Yoshida EM, Tacke F, Li Y, Guo X, Qi X. Risk of stroke in liver cirrhosis: a systematic review and meta-analysis. J Clin Gastroenterol 2020; 54 (01) 96-105
    CrossrefPubMedGoogle Scholar
  • 6 Jepsen P, Tapper EB, Deleuran T. et al. Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nation-wide cohort study. Hepatology 2021; 74 (05) 2725-2734
    CrossrefPubMedGoogle Scholar
  • 7 Lee H, Choi EK, Rhee TM. et al. Cirrhosis is a risk factor for atrial fibrillation: a nationwide, population-based study. Liver Int 2017; 37 (11) 1660-1667
    CrossrefPubMedGoogle Scholar
  • 8 Stone AC, Gaborcik JW, Smetana ME. Anticoagulation considerations in liver disease. Crit Care Nurs Q 2022; 45 (02) 156-166
    CrossrefPubMedGoogle Scholar
  • 9 Lee S-R, Lee H-J, Choi E-K. et al. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol 2019; 73 (25) 3295-3308
    CrossrefPubMedGoogle Scholar
  • 10 Coons EM, Staubes BA, Casey AL. et al. Direct oral anticoagulants versus warfarin for treatment of thrombosis or atrial fibrillation in patients with cirrhosis: a retrospective cohort study. Ann Pharmacother 2022; 56 (05) 533-540
    CrossrefPubMedGoogle Scholar
  • 11 Davis KA, Joseph J, Nisly SA. Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes. J Thromb Thrombolysis 2020; 50 (02) 457-461
    CrossrefPubMedGoogle Scholar
  • 12 Villa E, Cammà C, Marietta M. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (05) 1253.e4-1260.e4
    CrossrefPubMedGoogle Scholar
  • 13 Ai MH, Dong WG, Tan XP. et al. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2020; 32 (10) 1395-1400
    CrossrefPubMedGoogle Scholar
  • 14 Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol 2019; 113: 86-91
    CrossrefPubMedGoogle Scholar
  • 15 Ageno W, Gallus AS, Wittkowsky A. et al. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e44S-e88S
    CrossrefPubMedGoogle Scholar
  • 16 Perzborn E, Strassburger J, Wilmen A. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3 (03) 514-521
    CrossrefPubMedGoogle Scholar
  • 17 Jiménez D, Yusen RD, Ramacciotti E. Apixaban: an oral direct factor-xa inhibitor. Adv Ther 2012; 29 (03) 187-201
    CrossrefPubMedGoogle Scholar
  • 18 Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am J Med 2016; 129 (11S): S64-S72
    CrossrefPubMedGoogle Scholar
  • 19 Gitto S, Romanelli RG, Cellai AP. et al. Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis. Intern Emerg Med 2021; 16 (02) 339-347
    CrossrefPubMedGoogle Scholar
  • 20 Julia S, James U. Direct oral anticoagulants: a quick guide. Eur Cardiol 2017; 12 (01) 40-45
    CrossrefPubMedGoogle Scholar
  • 21 Ageno W, Beyer Westendorf J, Contino L. et al. Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Adv 2022; 6 (12) 3569-3578
    CrossrefPubMedGoogle Scholar
  • 22 Ponvilawan B, Chaisidhivej N, Kinnucan JAR. Efficacy and safety of direct oral anticoagulants in treatment of splanchnic vein thrombosis in cirrhotic patients: systematic review and meta-analysis. Am J Gastroenterol 2021; 116: S525-S526
    CrossrefPubMedGoogle Scholar
  • 23 Mohan BP, Aravamudan VM, Khan SR, Ponnada S, Asokkumar R, Adler DG. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: systematic review and meta-analysis. Ann Gastroenterol 2020; 33 (05) 521-527
    CrossrefPubMedGoogle Scholar
  • 24 Menichelli D, Ronca V, Di Rocco A, Pignatelli P, Marco Podda G. CAR. Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis. Eur J Clin Invest 2021; 51 (03) e13397
    CrossrefPubMedGoogle Scholar
  • 25 Wang L, Guo X, Xu X. et al. Anticoagulation favors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: results of a meta-analysis. Adv Ther 2021; 38 (01) 495-520
    CrossrefPubMedGoogle Scholar
  • 26 Zhang Z, Zhao Y, Han B, Zhu Z, Sun L, Cui X. The efficacy and safety of anticoagulants in the treatment of cirrhotic portal vein thrombosis: a systematic review and meta-analysis. Clin Appl Thromb Hemost 2022; 28: 107 60296221104797
    CrossrefPubMedGoogle Scholar
  • 27 Huang ZC, Li CQ, Liu XY. et al. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review. Cardiovasc Drugs Ther 2021; 35 (06) 1205-1215
    CrossrefPubMedGoogle Scholar
  • 28 Koh JH, Liew ZH, Ng GK. et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis. Dig Liver Dis 2022; 54 (01) 56-62
    CrossrefPubMedGoogle Scholar
  • 29 Hoolwerf EW, Kraaijpoel N, Büller HR, van Es N. Direct oral anticoagulants in patients with liver cirrhosis: a systematic review. Thromb Res 2018; 170: 102-108
    CrossrefPubMedGoogle Scholar
  • 30 Chen H, Lei J, Liang S, Luo G, Deng M, Lü M. Safety and efficacy of anticoagulation in patients with cirrhosis: a meta-analysis. Can J Gastroenterol Hepatol 2021; 2021: 8859602
    CrossrefPubMedGoogle Scholar
  • 31 Ali F, Laskova A, Misra S. et al. Non-vitamin K antagonist oral anticoagulation vs standard of care for the treatment of portal venous thrombosis in cirrhotic patients; a systematic review with meta-analysis. Am J Gastroenterol 2021; 116: S544-S545
    CrossrefPubMedGoogle Scholar
  • 32 Lee ZY, Suah BH, Teo YH. et al. Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: a systematic review and meta-analysis. Am J Cardiovasc Drugs 2022; 22 (02) 157-165
    CrossrefPubMedGoogle Scholar
  • 33 de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol 2022; 76 (04) 959-974
    CrossrefPubMedGoogle Scholar
  • 34 Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis 2021; 22 (04) 176-186
    CrossrefPubMedGoogle Scholar
  • 35 Villa E, Bianchini M, Blasi A. et al; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, ; European Association for the Study of the Liver. EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022; 76 (05) 1151-1184
    CrossrefPubMedGoogle Scholar
  • 36 O'Shea RS, Davitkov P, Ko CW. et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis. Gastroenterology 2021; 161 (05) 1615.e1-1627.e1
    PubMedGoogle Scholar
  • 37 Sundararajan T, Chandrasekar VT, Siddiqui H. et al. Risk of major bleeding events between direct oral anticoagulants and traditional anticoagulants in patients with cirrhosis: systematic review and meta-analysis. Hepatology 2020; 72: 1149A-1150A
    PubMedGoogle Scholar
  • 38 Kostev K, Loosen S, Roderburg C, Tanislav C. Direct oral anticoagulants versus preprohormone in patients with cirrhosis and the risk of gastrointestinal bleeding. Ann Pharmacother 2022; 56 (08) 967
    CrossrefPubMedGoogle Scholar
  • 39 Oldham M, Palkimas S, Hedrick A. Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis. Ann Pharmacother 2022; 56 (07) 782-790
    CrossrefPubMedGoogle Scholar
  • 40 Yoo SY, Kim E, Nam GB. et al. Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation. Korean J Intern Med (Korean Assoc Intern Med) 2022; 37 (03) 555-566
    PubMedGoogle Scholar
  • 41 Yao W, Feng Y, Liu T. et al. Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: a randomized clinical trial. EXCLI J 2021; 20: 537-549
    PubMedGoogle Scholar
  • 42 Serper M, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE. Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology 2021; 73 (01) 219-232
    CrossrefPubMedGoogle Scholar
  • 43 Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Mascarenhas J, Schiano T. Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis. Dig Dis Sci 2021; 66 (10) 3619-3629
    CrossrefPubMedGoogle Scholar
  • 44 Ilcewicz HN, Martello JL, Piechowski K. Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis. J Am Coll Clin Pharm 2020; 3: 147-148
    PubMedGoogle Scholar
  • 45 Jones K, Pham C, Aguilar C, Sheth S. Retrospective review on the safety and efficacy of direct oral anticoagulants compared with warfarin in patients with cirrhosis. Fed Pract 2020; 37 (10) 479-485
    PubMedGoogle Scholar
  • 46 Hadi Y, Naqvi S, Khan AY, Kupec J. Direct acting oral anticoagulant use is safe and effective in patients with cirrhosis. Gastroenterology 2020; 158: S-1469
    CrossrefPubMedGoogle Scholar
  • 47 Naqvi SF, Hadi Y, Ul Jannat FR. et al. Use of direct acting oral anticoagulants for pulmonary embolism and DVT in patients with cirrhosis. Chest 2020; 158: A2209
    CrossrefPubMedGoogle Scholar
  • 48 Nagaoki Y, Aikata H, Daijyo K. et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res 2018; 48 (01) 51-58
    CrossrefPubMedGoogle Scholar
  • 49 Shatzel J, Chandran R, Gardiner S. et al. The safety of low molecular weight heparin, direct oral anticoagulants, & warfarin in patients with chronic liver disease; analysis of 932 patients from the RIETE database. Res Pract Thromb Haemost 2018; 2: 331
    PubMedGoogle Scholar
  • 50 Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol 2017; 98 (04) 393-397
    CrossrefPubMedGoogle Scholar
  • 51 Intagliata NM, Henry ZH, Maitland H. et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci 2016; 61 (06) 1721-1727
    CrossrefPubMedGoogle Scholar
  • 52 Jarboe L, Dadlani A, Bandikatla S, Wade R, Barve A. Drug use evaluation of direct oral anticoagulants (DOACs) in patients with advanced cirrhosis. Cureus 2022; 14 (04) e24029
    PubMedGoogle Scholar
  • 53 Zhan C, Prabhu V, Kang SK. et al. Comparison of non-tumoral portal vein thrombosis management in cirrhotic patients: tips versus anticoagulation versus no treatment. J Clin Med 2021; 10 (11) 10
    CrossrefPubMedGoogle Scholar
  • 54 De Gottardi A, Trebicka J, Klinger C. et al; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int 2017; 37 (05) 694-699
    CrossrefPubMedGoogle Scholar
  • 55 Mort JF, Davis JPE, Mahoro G, Stotts MJ, Intagliata NM, Northup PG. Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis. Clin Gastroenterol Hepatol 2021; 19 (07) 1436-1442
    CrossrefPubMedGoogle Scholar
  • 56 Rusin G, Ząbczyk M, Natorska J, Malinowski KP, Undas A. Direct oral anticoagulants in patients with atrial fibrillation and liver cirrhosis: a single-center experience. Kardiol Pol 2021; 79 (7–8): 864-866
    CrossrefPubMedGoogle Scholar
  • 57 Werońska A, Papuga-Szela E, Broniatowska E, Undas A. Reduced–dose apixaban and dabigatran in patients with advanced liver cirrhosis and venous thromboembolism: a case series. Pol Arch Intern Med 2021; 131 (7–8): 762-765
    PubMedGoogle Scholar
  • 58 Cisak KI, Asante D, Grill DE, Ashrani AA. Efficacy and safety of direct oral anticoagulants in patients with cirrhosis—single institution experience. Blood 2018; 132 (Suppl 1): 2525
    CrossrefPubMedGoogle Scholar
  • 59 Kunk PR, Collins H, Palkimas S, Intagliata NM, Maitland HS. Direct oral anticoagulants in patients with cirrhosis appear safe and effective. Blood 2016; 128 (22) 3827
    CrossrefPubMedGoogle Scholar
  • 60 Virstyuk N, Matkovska N, Vakalyuk I, Virstyuk O. Effect of rivaroxaban on hypercoagulopathy risk factors in liver cirrhosis patients with nonvalvular atrial fibrillation. J Hepatol 2020; 73: S767
    CrossrefPubMedGoogle Scholar
  • 61 Walker C, Aljudaibi B, Martens J. et al. Evaluation of the efficacy of apixaban use for the treatment of portal vein thrombosis in patients with cirrhosis. Hepatology 2019; 70 (01) 265
    PubMedGoogle Scholar
  • 62 Wang M, Wang Y, Zhang G. et al. Efficacy and safety of rivaroxaban in portal vein thrombosis in patients with liver decompensated cirrhosis. J Hepatol 2020; 73: S767-S768
    CrossrefPubMedGoogle Scholar
  • 63 Nisly SA, Mihm AE, Gillette C, Davis KA, Tillett J. Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis. J Thromb Thrombolysis 2021; 52 (03) 817-827
    CrossrefPubMedGoogle Scholar
  • 64 Ng CH, Tan DJH, Nistala KRY. et al. A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis. Hepatol Int 2021; 15 (05) 1196-1206
    CrossrefPubMedGoogle Scholar
  • 65 Lapumnuaypol K, DiMaria C, Chiasakul T. Safety of direct oral anticoagulants in patients with cirrhosis: a systematic review and meta-analysis. QJM 2019; 112 (08) 605-610
    CrossrefPubMedGoogle Scholar
  • 66 Chokesuwattanaskul R, Thongprayoon C, Bathini T. et al. Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a systematic review and meta-analysis. Dig Liver Dis 2019; 51 (04) 489-495
    CrossrefPubMedGoogle Scholar
  • 67 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124 (15) 2450-2458
    CrossrefPubMedGoogle Scholar
  • 68 van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (03) 320-328
    CrossrefPubMedGoogle Scholar
  • 69 Gunasekaran K, Rajasurya V, Devasahayam J. et al. A review of the incidence diagnosis and treatment of spontaneous hemorrhage in patients treated with direct oral anticoagulants. J Clin Med 2020; 9 (09) 9
    CrossrefPubMedGoogle Scholar
  • 70 Sardar P, Chatterjee S, Lavie CJ. et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol 2015; 179: 279-287
    CrossrefPubMedGoogle Scholar
  • 71 Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017; 15 (11) 1674.e3-1683.e3
    CrossrefPubMedGoogle Scholar
  • 72 Prelipcean CC, Fierbinteanu-Braticevici C, Drug VL, Lăcătuşu C, Mihai B, Mihai C. Liver cirrhosis–procoagulant stasis [in Romanian]. Rev Med Chir Soc Med Nat Iasi 2011; 115 (03) 678-685
    PubMedGoogle Scholar
  • 73 Drolz A, Horvatits T, Roedl K. et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis. Hepatology 2016; 64 (02) 556-568
    CrossrefPubMedGoogle Scholar
  • 74 Ow TW, Fatourou E, Rabinowich L. et al. Prevalence of bleeding and thrombosis in critically ill patients with chronic liver disease. Thromb Haemost 2022; 122 (06) 1006-1016
    Article in Thieme ConnectPubMedGoogle Scholar
  • 75 Sasso R, Rockey DC. Anticoagulation therapy in patients with liver cirrhosis is associated with an increased risk of variceal hemorrhage. Am J Med 2019; 132 (06) 758-766
    CrossrefPubMedGoogle Scholar
  • 76 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53 (01) 1-16
    CrossrefPubMedGoogle Scholar
  • 77 Tran H, Joseph J, Young L. et al; Australasian Society of Thrombosis and Haemostasis. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J 2014; 44 (06) 525-536
    CrossrefPubMedGoogle Scholar
  • 78 Bolek T, Samoš M, Škorňová I. et al. Dabigatran levels in elderly patients with atrial fibrillation: first post-marketing experiences. Drugs Aging 2018; 35 (06) 539-544
    CrossrefPubMedGoogle Scholar
  • 79 Chen WC, Chen YH, Hsu PI. et al. Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome. BioMed Res Int 2014; 2014: 463767
    PubMedGoogle Scholar
  • 80 Lanas-Gimeno A, Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin Drug Saf 2017; 16 (06) 673-685
    CrossrefPubMedGoogle Scholar
  • 81 Di Nisio M, Valeriani E, Riva N, Schulman S, Beyer-Westendorf J, Ageno W. Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J Thromb Haemost 2020; 18 (07) 1562-1568
    CrossrefPubMedGoogle Scholar
  • 82 Shin KH, Kim IS, Lee HJ. et al. Thromboelastographic evaluation of coagulation in patients with liver disease. Ann Lab Med 2017; 37 (03) 204-212
    CrossrefPubMedGoogle Scholar
  • 83 Kohli R, Shingina A, New S. et al. Thromboelastography parameters are associated with cirrhosis severity. Dig Dis Sci 2019; 64 (09) 2661-2670
    CrossrefPubMedGoogle Scholar
  • 84 He Y, Yuan S, Guo X. et al. Association of thromboelastography profile with severity of liver cirrhosis and portal venous system thrombosis. BMC Gastroenterol 2021; 21 (01) 253
    CrossrefPubMedGoogle Scholar
  • 85 Lieber SR, Jiang Y, Moon A, Barritt AS. Bleeding events associated with anticoagulants and anti-platelets among a large u.s. cohort of privately-insured patients with compensated and decompensated cirrhosis. Hepatology 2019; 70 (01) 493-494
    PubMedGoogle Scholar
  • 86 Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007; 26 (02) 141-148
    CrossrefPubMedGoogle Scholar
  • 87 Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111 (09) 4471-4476
    CrossrefPubMedGoogle Scholar
  • 88 Efird LM, Mishkin DS, Berlowitz DR. et al. Stratifying the risks of oral anticoagulation in patients with liver disease. Circ Cardiovasc Qual Outcomes 2014; 7 (03) 461-467
    CrossrefPubMedGoogle Scholar
  • 89 Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med 2015; 26 (01) 23-29
    CrossrefPubMedGoogle Scholar
  • 90 Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 2017; 153 (02) 480.e1-487.e1
    CrossrefPubMedGoogle Scholar